Mandatory Notification of Trade
Please refer to the attached form of notification of transaction by primary insider under the DNO ASA Employee Synthetic Share Program.
This notification has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release
ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin
Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of
Questex’s IHIF EMEA 2024 Day 2 is Full of Insightful Discussions and Partnerships16.4.2024 20:06:33 CEST | Press release
LONDON, April 16, 2024 (GLOBE NEWSWIRE) -- Day two of Questex’s International Hospitality Investment Forum EMEA (IHIF EMEA) brought deep insights into macro travel trends, supply and demand, the drivers of profit, how capital is attracted and invested, how global level deals are done and how changing trends influence what owners, brands and operators do with the customer offering. The Capital Talks panel session is one of the most eagerly anticipated spots on the programme. In a discussion moderated by Kenneth Hatton, managing director, head of hotels, Europe at CBRE, IHIF EMEA delegates learned about the underlying trends supporting hospitality investment. Representatives from KSL Capital Partners, Starwood Capital and AXA Investment Managers talked about the finer points of the current hospitality landscape. Josh Cleveland, partner & head of EMEA, real estate, StepStone Group said that hospitality’s “strong inflation hedge” had convinced the firm to invest in the asset class in an in
Markets EQ Announces Titanium: The Next Evolution in AI-Powered Financial Communication16.4.2024 19:02:14 CEST | Press release
New York, NY, April 16, 2024 (GLOBE NEWSWIRE) -- Markets EQ, the first to fuse voice tones with language in a generative AI platform for corporate communications, today unveiled Titanium. Built for the discerning needs of investor relations and financial communications professionals, Titanium offers unparalleled AI security, marking a leap forward in securely navigating pre- and post-earnings calls with advanced AI insights. Titanium is designed to bridge the critical value gaps in financial narratives, enabling users to craft and refine their investor stories with precision. Its unique capabilities ensure that professionals are equipped with the best-in-class linguistic and tonal AI tools, transforming earnings call preparation and analysis into a more strategic and insightful process, saving time on reviews, providing real-time feedback, and securing sensitive information. “At Markets EQ, we recognize the dual imperative of security and intelligence in financial communications. Titan